Roche's soaring Vabysmo sales challenge Regeneron's Eylea fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Regeneron Misses Profit Estimates on Weaker Eylea and Dupixent Sales usnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usnews.com Daily Mail and Mail on Sunday newspapers.
Sales of Roche's juggernaut Vabysmo rout the analyst consensus fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
J&J lands two cancer drugs on Clarivate list of Drugs to Watch fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022. Regeneron has set its hopes on a higher-dose version of Eylea.